TRPV1 Antagonist DWP05195 Induces ER Stress-Dependent Apoptosis through the ROS-p38-CHOP Pathway in Human Ovarian Cancer Cells
CANCERS
Authors: Wang, Yi-Yue; Lee, Kyung-Tae; Lim, Myong Cheol; Choi, Jung-Hye
Abstract
In addition to their analgesic activity, transient receptor potential vanilloid 1 (TRPV1) agonists and antagonists demonstrate profound anti-cancer activities in various human cancers. In the present study, we investigated the anti-cancer activity of a novel TRPV1 antagonist, DWP05195, and evaluated its molecular mechanism in human ovarian cancer cells. DWP05195 demonstrated potent growth inhibitory effects in all five ovarian cancer cell lines examined. DWP05195 induced apoptosis through the activation of caspase-3, -8, and -9. DWP05195 induced C/EBP homologous protein (CHOP) expression and endoplasmic reticulum (ER) stress. Sodium phenylbutyrate (4-PBA), an ER-stress inhibitor, and CHOP knockdown significantly suppressed DWP5195-induced cell death. DWP05195-enhanced CHOP expression stimulated intrinsic and extrinsic apoptotic pathways through the regulation of Bcl2-like11 (BIM), death receptor 4 (DR4), and DR5. DWP05195-induced cell death was associated with increased reactive oxygen species (ROS) levels and p38 pathway activation. Pre-treatment with the antioxidant N-acetyl-L-cysteine (NAC) significantly suppressed DWP05195-induced CHOP expression and p38 activation. Inhibition of NADPH oxidase (NOX) through p47phox knockdown abolished DWP05195-induced CHOP expression and cell death. Taken together, the findings indicate that DWP05195 induces ER stress-induced apoptosis via the ROS-p38-CHOP pathway in human ovarian cancer cells.
A new lymphoid-primed progenitor marked byDach1downregulation identified with single cell multi-omics
NATURE IMMUNOLOGY
Authors: Amann-Zalcenstein, Daniela; Tian, Luyi; Schreuder, Jaring; Tomei, Sara; Lin, Dawn S.; Fairfax, Kirsten A.; Bolden, Jessica E.; McKenzie, Mark D.; Jarratt, Andrew; Hilton, Adrienne; Jackson, Jacob T.; Di Rago, Ladina; McCormack, Matthew P.; de Graaf, Carolyn A.; Stonehouse, Olivia; Taoudi, Samir; Alexander, Warren S.; Nutt, Stephen L.; Ritchie, Matthew E.; Ng, Ashley P.; Naik, Shalin H.
Abstract
Exploring transcriptional heterogeneity of cKit(+)Sca1(+)HSPCs using single cell RNA-sequencing, Naik and colleagues identify a population termed 'lymphoid primed progenitors' as the earliest stage of lymphoid lineage commitment, marked by downregulation of the stem/myeloid transcription factor Dach1. A classical view of blood cell development is that multipotent hematopoietic stem and progenitor cells (HSPCs) become lineage-restricted at defined stages. Lin(-)c-Kit(+)Sca-1(+)Flt3(+)cells, termed lymphoid-primed multipotent progenitors (LMPPs), have lost megakaryocyte and erythroid potential but are heterogeneous in their fate. Here, through single-cell RNA sequencing, we identify the expression ofDach1and associated genes in this fraction as being coexpressed with myeloid/stem genes but inversely correlated with lymphoid genes. Through generation ofDach1-GFP reporter mice, we identify a transcriptionally and functionally uniqueDach1-GFP(-)subpopulation within LMPPs with lymphoid potential with low to negligible classic myeloid potential. We term these 'lymphoid-primed progenitors' (LPPs). These findings define an early definitive branch point of lymphoid development in hematopoiesis and a means for prospective isolation of LPPs.